Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke

Alastair J.S. Webb, BMBCh, DPhil; Sara Mazzucco, MD, PhD; Linxin Li, DPhil; Peter M. Rothwell, FMedSci

Background and Purpose—Visit-to-visit and day-to-day blood pressure (BP) variability (BPV) predict an increased risk of cardiovascular events but only reflect 1 form of BPV. Beat-to-beat BPV can be rapidly assessed and might also be predictive.

Methods—In consecutive patients within 6 weeks of transient ischemic attack or nondisabling stroke (Oxford Vascular Study), BPV (coefficient of variation) was measured beat-to-beat for 5 minutes (Finometer), day-to-day for 1 week on home monitoring (3 readings, 3x daily), and on awake ambulatory BP monitoring. BPV after 1-month standard treatment was related (Cox proportional hazards) to recurrent stroke and cardiovascular events for 2 to 5 years, adjusted for mean systolic BP.

Results—Among 520 patients, 26 had inadequate beat-to-beat recordings, and 22 patients were in atrial fibrillation. Four hundred fifty patients had all forms of monitoring. Beat-to-beat BPV predicted recurrent stroke and cardiovascular events independently of mean systolic BP (hazard ratio per group SD, stroke: 1.47 [1.12–1.91]; P=0.005; cardiovascular events: 1.41 [1.08–1.83]; P=0.01), including after adjustment for age and sex (stroke: 1.47 [1.12–1.92]; P=0.005) and all risk factors (1.40 [1.00–1.94]; P=0.047). Day-to-day BPV was less strongly associated with stroke (adjusted hazard ratio, 1.29 [0.97–1.71]; P=0.08) but similarly with cardiovascular events (1.41 [1.09–1.83]; P=0.009). BPV on awake ambulatory BP monitoring was nonpredictive (stroke: 0.89 [0.59–1.35]; P=0.59; cardiovascular events: 1.08 [0.77–1.52]; P=0.65). Despite a weak correlation (r=0.119; P=0.02), beat-to-beat BPV was associated with risk of recurrent stroke independently of day-to-day BPV (1.41 [1.05–1.90]; P=0.02).

Conclusions—Beat-to-beat BPV predicted recurrent stroke and cardiovascular events, independently of mean systolic BP and risk factors but short-term BPV on ambulatory BP monitoring did not. Beat-to-beat BPV may be a useful additional marker of cardiovascular risk.

Key Words: cardiovascular diseases ■ humans ■ hypertension ■ risk factors ■ stroke

Patients with episodic hypertension in clinic after a previous transient ischemic attack or stroke have a high risk of recurrent stroke,1,2 residual visit-to-visit variability in blood pressure (BP) on antihypertensive treatment has a poor prognosis, despite good control of mean BP,3 and benefits of some antihypertensive drugs in the prevention of stroke may partly result from reduced variability in systolic BP (SBP).4,5 Home day-to-day BP variability (home BP monitoring [HBPM] BPV) is similarly associated with an increased stroke risk,5,6 particularly for variability in morning BP6 and is reduced by similar medications. In contrast, short-term BPV on awake ambulatory BP monitoring (ABPM) is only weakly predictive of cardiovascular events,2 as is within-visit variability in office BP, with short-term BPV also correlating poorly with visit-to-visit BPV.1,2 However, the predictive value of beat-to-beat BPV for 5 minutes has not been determined.

Beat-to-beat BPV for 5 minutes is only weakly correlated with day-to-day BPV on HBPM and premorbid visit-to-visit BPV but shares the same physiological associations, suggestive of a similar pathophysiology.7 Increased beat-to-beat BPV8 and diminished baroreceptor sensitivity (derived from beat-to-beat BP monitoring)9 are potentially associated with a worse outcome after a major acute stroke and may be associated with an increased risk of recurrent events.8 However, previous studies were small with significant methodological problems. Therefore, we determined the predictive value

© 2017 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.117.019107

Received August 15, 2017; final revision received October 13, 2017; accepted October 26, 2017.
From the Department of Clinical Neurosciences, Centre for Prevention of Stroke and Dementia, University of Oxford, United Kingdom.
Guest Editor for this article was Natalia Rost, MD, MPH.
The views expressed in this article are those of the author(s) and not necessarily of the National Health Service, the National Institute for Health Research, or the Department of Health.
The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.117.019107/-/DC1.
Correspondence to Alastair J.S. Webb, BMBCh, DPhil, Department of Clinical Neurosciences, Centre for Prevention of Stroke and Dementia, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DU, United Kingdom. E-mail alastair.webb@ndcn.ox.ac.uk
© 2017 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.117.019107
of beat-to-beat BPV in a prospective cohort of patients with recent transient ischemic attack or minor stroke.

Materials and Methods

Requests for access to the data and analysis tools in this article will be openly considered. Please contact P.M.R. for further information.

Study Population

Consecutive patients were recruited between September 2010 and 2015 from the OXVASC (Oxford Vascular Study) transient ischemic attack and minor stroke clinic. The OXVASC population consists of 92,728 individuals registered with 100 primary-care physicians in Oxfordshire, United Kingdom. All consenting patients underwent a standardized medical history and examination, ECG, blood tests, and a stroke protocol magnetic resonance imaging brain and contrast-enhanced magnetic resonance angiography (or CT brain and carotid Doppler ultrasound or CT angiogram), an echocardiogram, and 5-day ambulatory cardiac monitoring. All patients were reviewed by a study physician, the diagnosis verified by the senior study neurologist (P.M.R.), etiology determined by a panel of stroke neurologists, and were followed-up face-to-face at 1, 3, 6, and 12 months, and 62, 5, or 10 years. Recurrent events were determined at face-to-face follow-up and by multiple overlapping methods of ascertaining, including daily review of hospital admissions, review of death certificates and coroner’s records, manual review of general practitioner records, and linkage to hospital event statistics and death registries.

Participants were excluded if they were <18 years of age, cognitively impaired (Mini-Mental State Examination<23), pregnant; had a recent myocardial infarction, unstable angina, heart failure (New York Heart Association, 3–4) or ejection fraction, <40%, or untreated bilateral carotid stenosis (>70%); and if they had atrial fibrillation during testing. The study was approved by the Oxfordshire Research Ethics Committee.

BP Measurement

Two sitting clinic BPs, 5 minutes apart, were measured at ascertainment and 1 month in the nondominant arm, by trained personnel after 5 minutes of rest. From ascertainment, patients agreeing to perform HBPM performed 3 home readings for 10 minutes, 3x daily (after waking, midmorning, and evening) with a Bluetooth-enabled, regularly calibrated telemetric IEM Stabil-o-Graph or A&D UA-767 BT. Patients were instructed to relax in a chair for 5 minutes before measuring BP in the nondominant arm or the higher-reading arm when the mean SBP differed by >20 mm Hg. Anonymized measures were securely transmitted via Bluetooth radio and a mobile phone to a password-protected website (+ Medical, Abingdon, United Kingdom) and medication prescribed according to guidelines, most frequently with perindopril, indapamide, or amiodipine, to a target of <130/80. The day before the 1-month follow-up, ABPM was performed with an A&D TM-2430 monitor in the nondominant arm. BP was measured every 30 minutes during the day and 60 minutes at night. Beat-to-beat BPV was measured for 5 minutes at the ascertainment visit or 1-month clinic in a quiet, dimly lit, temperature-controlled room (21–23°C). Continuous 3-lead ECG and finger arterial BP were acquired at 200 Hz (Finometer MIDI) via a Powerlab 8/35 (ADInstruments), from the nondominant arm when possible. Automated calibration was performed until the recording was stable, but turned off during each test, and readings calibrated offline to the mean of 2 supine, oscillometric brachial readings.

Analysis

BPV on beat-to-beat monitoring was calculated for 5 minutes. Ectopic beats and artefacts were automatically detected, visually reviewed, and removed by linear interpolation. Patients in atrial fibrillation during the recording were excluded. Variability was calculated as the coefficient of variation (CV) about a linear regression across 5 minutes to remove drift in the waveform (residual CV). HBPM variability was derived from the last 7 days of recording before the 1-month follow-up visit, from the average SBP or diastolic BP (DBP) calculated from the last 2 readings of each cluster of 3. Awake BPV on ABPM was derived after automated and manual exclusion of artefacts according to standard criteria. BPV was derived as the CV (CV=SD/mean) and the residual CV about a moving average on HBPM. Reproducibility of BPV on HBPM was determined in 100 patients between the second and third weeks of monitoring as Pearson r and intraclass correlation coefficient. In 50 patients, beat-to-beat BPV was measured at baseline and the 1-month visit according to the same protocol to determine reproducibility of measurement by Pearson r and the intraclass correlation coefficient.

Risk of recurrent cardiovascular events was determined per unit increase in mean and variability in SBP or DBP and per SD for the population for each method of measurement by Cox proportional hazards regression, with and without adjustment for age, sex, and major cardiovascular risk factors (hypertension, diabetes mellitus, family history, smoking, atrial fibrillation, and dyslipidemia), and in combined models adjusting for other measures of BPV. The effect of adjustment of beat-to-beat and day-to-day BPV for regression to the mean was estimated by scaling the difference between the mean BPV for each quartile of BPV and the population mean by the intraclass correlation coefficient.

Literature Review

PubMed and EMBASE were searched from inception until March 1, 2017, with the terms (“blood pressure” OR “BP” OR “hypertension” OR “BPV” OR “baroreflex” OR “BRS” OR “baroreflex sensitivity”) AND (“stroke” OR “cerebrovascular”) OR “cerebrovascular accident” OR “cerebrovascular event” OR “cerebrovascular” OR “leukoaraiosis” OR “white matter hyper-intensities” OR “white matter disease” OR “small vessel disease”). All articles reporting recurrent cardiovascular events per unit of beat-to-beat BPV were identified.

Results

Of 520 patients, 26 had poor-quality recordings because of excessive ectopies or poor-quality finometer recordings because of poor peripheral circulation, whereas 22 were excluded from beat-to-beat analyses because of atrial fibrillation during the recording, which limits the accuracy of BPV measurement, leaving 472 patients with valid beat-to-beat recordings. Four hundred sixty-six of 520 patients had adequate HBPM (2.9 readings per cluster for median 29 days) and 461 of 520 had adequate ABPM (Table 1), with 405 patients with adequate monitoring undergoing all forms of recording. There were weak-positive associations between BPV measured with different methods (beat-to-beat CV versus HBPM residual CV: r=0.119, P=0.017; beat-to-beat CV versus awake SBP CV: r=0.04, P=0.37; HBPM residual CV versus awake SBP CV: r=0.20, P=0.001) but limited associations with demographic variables (Table 1).

BPV on beat-to-beat monitoring in the 405 patients undergoing all forms of monitoring was associated with an increased risk of ischemic stroke, any stroke, and all cardiovascular events, independently of mean SBP (Table 2), before and after adjustment for age and sex, with a significant association with the risk of recurrent ischemic stroke remaining after adjustment for other cardiovascular risk factors (hazard ratio per SD, 1.40 [1.00–1.94]; P=0.047). Relationships were similar for all patients undergoing each form of monitoring and largely unchanged by adjustment for mean SBP (Table 1 in the online-only Data Supplement). The hazard ratio per 1% increase in beat-to-beat CV for stroke was 1.24 (1.07–1.43; P=0.004; Table II in the online-only Data Supplement).
Stroke January 2018

Table 1. Demographics of 472 Patients With Adequate Beat-to-Beat Recording in Sinus Rhythm During the Recording

<table>
<thead>
<tr>
<th>Quartiles of Beat-to-Beat Systolic BPV</th>
<th>All (n=472)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (n=118)</td>
<td>2 (n=118)</td>
<td>3 (n=118)</td>
</tr>
<tr>
<td>Age, y</td>
<td>64.9 (13.2)</td>
<td>66.2 (13.2)</td>
</tr>
<tr>
<td>Men (%)</td>
<td>60 (51)</td>
<td>69 (59)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>8 (6.8)</td>
<td>9 (7.6)</td>
</tr>
<tr>
<td>Family history</td>
<td>30 (32)</td>
<td>32 (31)</td>
</tr>
<tr>
<td>Hyperlipidemia</td>
<td>36 (31)</td>
<td>36 (31)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>18 (15)</td>
<td>17 (15)</td>
</tr>
<tr>
<td>Beat-to-beat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP mean</td>
<td>127 (18)</td>
<td>125 (19)</td>
</tr>
<tr>
<td>SBP rCV</td>
<td>2.2 (0.5)</td>
<td>3.3 (0.3)</td>
</tr>
<tr>
<td>DBP mean</td>
<td>74 (9)</td>
<td>72 (11)</td>
</tr>
<tr>
<td>DBP rCV</td>
<td>2.4 (1.3)</td>
<td>7.5 (4.3)</td>
</tr>
<tr>
<td>HBPM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP mean</td>
<td>122 (15)</td>
<td>122 (21)</td>
</tr>
<tr>
<td>SBP rCV</td>
<td>4.7 (2.1)</td>
<td>4.4 (1.8)</td>
</tr>
<tr>
<td>Awake ABPM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP mean</td>
<td>126 (11)</td>
<td>127 (15)</td>
</tr>
<tr>
<td>SBP CV</td>
<td>12 (3.2)</td>
<td>12 (3.9)</td>
</tr>
<tr>
<td>Asleep ABPM:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP mean</td>
<td>116 (15)</td>
<td>113 (20)</td>
</tr>
<tr>
<td>SBP CV</td>
<td>11 (4.8)</td>
<td>11 (5.7)</td>
</tr>
<tr>
<td>Creatinine</td>
<td>74 (21)</td>
<td>79 (22)</td>
</tr>
<tr>
<td>BMI</td>
<td>27 (5.1)</td>
<td>26 (3.8)</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>5.1 (1.3)</td>
<td>5.3 (3.0)</td>
</tr>
</tbody>
</table>

ABPM indicates ambulatory blood pressure monitoring; BMI, body mass index; BPV, blood pressure variability; CV, coefficient of variation; DBP, diastolic blood pressure; HBPM, home blood pressure monitoring; rCV, residual coefficient of variation; and SBP, systolic blood pressure. *P<0.05.

In models including both beat-to-beat and HBPM BPV, beat-to-beat BPV was more predictive of the risk of recurrent stroke, whereas BPV on HBPM was more predictive of the risk of all cardiovascular events (Table V in the online-only Data Supplement). Similarly, mean BPV on beat-to-beat monitoring was significantly lower in patients unaffected by stroke than affected patients, whereas BPV on home monitoring was significantly lower compared with patients dying or experiencing outcome event (Table VI in the online-only Data Supplement).

Two hundred nineteen abstracts of 960 search responses were potentially relevant, with 34 articles reviewed in full. No study reported the risk of recurrent cardiovascular events per change in beat-to-beat BPV. As in our previous meta-analysis, the risk of a poor outcome after acute stroke was associated with both SBP variability (hazard ratio, 1.07 [0.9–1.2]) and DBP variability (hazard ratio, 1.33 [1.1–1.7]), whereas a reduced baroreceptor sensitivity was associated with poor outcome after stroke or myocardial infarction.
Discussion

BPV predicted the risk of recurrent stroke and all cardiovascular events on 5 minutes of beat-to-beat BP monitoring, with a 4-fold increase in risk between the lowest and highest quartile of the population, with broadly similar predictive power to BPV on day-to-day monitoring.

Residual visit-to-visit variability in BP on antihypertensive treatment has a poor prognosis, despite good control of mean BP, with an increased risk of stroke and all cardiovascular events, and benefits of some antihypertensive drugs in the prevention of stroke seem to be due partly to reduced variability in SBP. However, more rapid assessment and control of BPV would be clinically useful, especially in the acute phase after transient ischemic attack or stroke. BPV on home BP monitoring is also predictive of recurrent strokes and all cardiovascular events and can be assessed for days but still poses practical challenges in retrieving and analyzing equipment and readings. Our study shows that a rapid, 5-minute assessment of beat-to-beat BPV may have similar prognostic significance compared with HBPM. If affected by antihypertensive medication in the same way as visit-to-visit and HBPM BPV, beat-to-beat BPV could be a useful index to guide antihypertensive treatment decisions. However, we found only a weak correlation between BPV on different methods of measurement, yet they were independently related to outcomes. This is consistent with the weak relationship between within-visit and between-visit BPV in previous analyses of the ASCOT trial (Anglo-Scandinavian Cardiac Outcomes Trial). Therefore, BPV on beat-to-beat and home monitoring may well be a complementary measure, potentially reflecting different pathophysiological mechanisms leading to stroke.

We have demonstrated previously that home and beat-to-beat BPV are associated with a similar underlying physiological phenotype, including increased arterial stiffness, aortic pulsatility, reduced baroreceptor gain, and increased cardiovascular reactivity to stress. Furthermore, patients with an acute stroke have increased beat-to-beat BPV and reduced baroreceptor gain, which is associated with increased mortality and is partly dependent on stroke location. However, the precise mechanism by which BPV is associated with an increased risk of recurrent stroke is unclear. This may reflect either the effects of associated physiological indices (arterial stiffness, pulsatility, and cerebrovascular reactivity) or direct effects of beat-to-beat BPV itself. However, beat-to-beat BPV is a composite measure of multiple physiological processes, including irregular episodic components and rhythmic components related to breathing and to underlying autonomic rhythms (ie, low frequency oscillations at 0.04–0.15 Hz), and its prognostic significance may also reflect multiple pathophysiological processes.

Our study has some limitations. First, some patients were excluded because of poor-quality recordings, either because of poor peripheral circulation, excess ectopy, or atrial fibrillation during the recording. However, this reflects the strength of study, which included a consecutively recruited, unselected elderly population with acute events. Second, although statistical power to compare different measures of BPV was limited by the relatively small number of recurrent vascular events, the study is nevertheless the largest study of the prognostic significance of beat-to-beat SBP variability in patients with stroke. Third, BPV was estimated after initiation of antihypertensive treatment, which may affect BPV and its association with recurrent events. However, this also largely removes the confounding
Conclusions

Beat-to-beat BPV was a novel predictor of the risk of recurrent stroke and may be complementary to BPV on day-to-day home BP monitoring, may aid in risk stratification, and may help identify independently treatable mechanisms to reduce the risk of stroke.

Acknowledgments

We acknowledge the use of facilities of the Acute Vascular Imaging Centre and the Cardiovascular Clinical Research Facility, University of Oxford.

Sources of Funding

The Oxford Vascular Study is funded by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Wellcome Trust, Wolfson Foundation, British Heart Foundation, and the European Unions Horizon 2020 Programme (grant 666881, SVDs@target). P.M. Rothwell is in receipt of an NIHR Senior Investigator award. A.J.S. Webb is funded by a Wellcome Trust Clinical Research Development Fellowship and British Heart Foundation Project grant.

Disclosures

None.

References


Prognostic Significance of Blood Pressure Variability on Beat-to-Beat Monitoring After Transient Ischemic Attack and Stroke
Alastair J.S. Webb, Sara Mazzucco, Linxin Li and Peter M. Rothwell

Stroke. 2018;49:62-67; originally published online December 11, 2017; doi: 10.1161/STROKEAHA.117.019107
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2017 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/49/1/62
Free via Open Access

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2017/12/11/STROKEAHA.117.019107.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/
ONLINE SUPPLEMENT

Prognostic significance of blood pressure variability on beat-to-beat monitoring after TIA and stroke

Alastair JS Webb† BMBCh DPhil, Sara Mazzucco† x MD PhD, Linxin Li Dphil, *Peter M Rothwell† FMedSci
Supplemental Table I. Risk of cardiovascular events during follow up, according to variability on each method of BP measurement. Results are presented as hazard ratios (Cox Proportional Hazards) per standard deviation for all patients undergoing each form of monitoring, with 95% confidence intervals, unadjusted and adjusted for age and gender. Bt-to-bt = beat to beat BP variability; p-val = p value;

<table>
<thead>
<tr>
<th>Measure</th>
<th>Ev</th>
<th>Unadjusted HR (95%CI)</th>
<th>p-val</th>
<th>Adjusted for Age/Gender HR (95%CI)</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ischaemic Stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>23</td>
<td>1.51 (1.14 - 1.99)</td>
<td>0.004</td>
<td>1.51 (1.14 - 2.01)</td>
<td>0.005</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>22</td>
<td>1.21 (0.88 - 1.66)</td>
<td>0.24</td>
<td>1.25 (0.91 - 1.73)</td>
<td>0.17</td>
</tr>
<tr>
<td>Awake</td>
<td>23</td>
<td>0.90 (0.61 - 1.32)</td>
<td>0.58</td>
<td>0.96 (0.65 - 1.44)</td>
<td>0.86</td>
</tr>
<tr>
<td><strong>Any Stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>34</td>
<td>1.50 (1.16 - 1.94)</td>
<td>0.002</td>
<td>1.48 (1.14 - 1.93)</td>
<td>0.004</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>33</td>
<td>1.28 (0.97 - 1.68)</td>
<td>0.08</td>
<td>1.27 (0.96 - 1.69)</td>
<td>0.09</td>
</tr>
<tr>
<td>Awake</td>
<td>33</td>
<td>0.95 (0.67 - 1.33)</td>
<td>0.75</td>
<td>1.00 (0.70 - 1.43)</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>All cause mortality</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>24</td>
<td>1.26 (0.90 - 1.76)</td>
<td>0.18</td>
<td>1.12 (0.79 - 1.58)</td>
<td>0.53</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>28</td>
<td>1.33 (0.99 - 1.78)</td>
<td>0.06</td>
<td>1.09 (0.76 - 1.56)</td>
<td>0.65</td>
</tr>
<tr>
<td>Awake</td>
<td>26</td>
<td>0.96 (0.66 - 1.40)</td>
<td>0.85</td>
<td>0.92 (0.61 - 1.38)</td>
<td>0.69</td>
</tr>
<tr>
<td><strong>CV Death or MACE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>37</td>
<td>1.41 (1.09 - 1.82)</td>
<td>0.009</td>
<td>1.35 (1.04 - 1.75)</td>
<td>0.02</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>38</td>
<td>1.33 (1.04 - 1.70)</td>
<td>0.02</td>
<td>1.26 (0.98 - 1.63)</td>
<td>0.08</td>
</tr>
<tr>
<td>Awake</td>
<td>38</td>
<td>0.95 (0.70 - 1.30)</td>
<td>0.76</td>
<td>1.04 (0.74 - 1.46)</td>
<td>0.83</td>
</tr>
<tr>
<td><strong>Death or MACE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>53</td>
<td>1.32 (1.05 - 1.65)</td>
<td>0.02</td>
<td>1.23 (0.97 - 1.54)</td>
<td>0.08</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>55</td>
<td>1.34 (1.10 - 1.65)</td>
<td>0.005</td>
<td>1.22 (0.98 - 1.53)</td>
<td>0.08</td>
</tr>
<tr>
<td>Awake</td>
<td>54</td>
<td>0.93 (0.71 - 1.21)</td>
<td>0.59</td>
<td>0.95 (0.72 - 1.27)</td>
<td>0.75</td>
</tr>
</tbody>
</table>
Supplemental Table II. Risk of cardiovascular events during follow up, according to variability on each method of BP measurement. Results are presented as hazard ratios (Cox Proportional Hazards) per 1% increase in CV for all patients undergoing each form of monitoring, with 95% confidence intervals, unadjusted and adjusted for age and gender. Bt-to-bt = beat to beat BP variability; p-val=p value;

<table>
<thead>
<tr>
<th>Measure</th>
<th>Event</th>
<th>Unadjusted</th>
<th>Adjusted for Age/Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>HR (95%CI)</td>
<td>p-val</td>
</tr>
<tr>
<td><strong>Ischaemic Stroke</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>23</td>
<td>1.24 (1.07 - 1.43)</td>
<td>0.004</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>22</td>
<td>1.11 (0.93 - 1.33)</td>
<td>0.24</td>
</tr>
<tr>
<td>Awake</td>
<td>23</td>
<td>0.97 (0.87 - 1.08)</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>Any Stroke</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>34</td>
<td>1.23 (1.08 - 1.41)</td>
<td>0.002</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>33</td>
<td>1.15 (0.98 - 1.34)</td>
<td>0.08</td>
</tr>
<tr>
<td>Awake</td>
<td>33</td>
<td>0.98 (0.89 - 1.08)</td>
<td>0.75</td>
</tr>
<tr>
<td><strong>All cause mortality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>24</td>
<td>1.13 (0.95 - 1.34)</td>
<td>0.18</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>28</td>
<td>1.17 (0.99 - 1.39)</td>
<td>0.06</td>
</tr>
<tr>
<td>Awake</td>
<td>26</td>
<td>0.99 (0.89 - 1.10)</td>
<td>0.85</td>
</tr>
<tr>
<td><strong>CV Death or MACE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>37</td>
<td>1.19 (1.05 - 1.36)</td>
<td>0.009</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>38</td>
<td>1.18 (1.02 - 1.35)</td>
<td>0.02</td>
</tr>
<tr>
<td>Awake</td>
<td>38</td>
<td>0.99 (0.9 - 1.08)</td>
<td>0.76</td>
</tr>
<tr>
<td><strong>Death or MACE</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>53</td>
<td>1.15 (1.03 - 1.29)</td>
<td>0.02</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>55</td>
<td>1.18 (1.05 - 1.33)</td>
<td>0.005</td>
</tr>
<tr>
<td>Awake</td>
<td>54</td>
<td>0.98 (0.91 - 1.06)</td>
<td>0.59</td>
</tr>
</tbody>
</table>
Supplemental Table III. Risk of cardiovascular events during follow up, according to variability on each method of DBP measurement. Results are presented as hazard ratios (Cox Proportional Hazards) per SD increase in CV of DBP for all patients undergoing each form of monitoring, with 95% confidence intervals, unadjusted and adjusted for age and gender. Bt-to-bt = beat to beat BP variability; p-val=p value;

<table>
<thead>
<tr>
<th>Measure</th>
<th>Ev</th>
<th>Unadjusted HR (95%CI)</th>
<th>p-val</th>
<th>Adjusted for Age/Gender HR (95%CI)</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischaemic Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>31</td>
<td>1.27 (0.98 - 1.66)</td>
<td>0.07</td>
<td>1.24 (0.95 - 1.63)</td>
<td>0.11</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>31</td>
<td>0.97 (0.64 - 1.48)</td>
<td>0.90</td>
<td>1.00 (0.64 - 1.54)</td>
<td>0.98</td>
</tr>
<tr>
<td>Awake</td>
<td>31</td>
<td>1.39 (0.99 - 1.95)</td>
<td>0.06</td>
<td>1.49 (1.03 - 2.16)</td>
<td>0.03</td>
</tr>
</tbody>
</table>

| Any Stroke |    |                       |       |                                     |       |
| Bt-to-bt | 34 | 1.22 (0.96 - 1.55)    | 0.10  | 1.20 (0.95 - 1.52)                  | 0.13  |
| Day-to-day | 33 | 1.06 (0.77 - 1.46)    | 0.74  | 1.06 (0.76 - 1.48)                  | 0.74  |
| Awake | 33 | 1.14 (0.83 - 1.57)    | 0.42  | 1.16 (0.83 - 1.63)                  | 0.39  |

| All cause mortality |    |                       |       |                                     |       |
| Bt-to-bt | 24 | 1.20 (0.90 - 1.60)    | 0.21  | 1.09 (0.81 - 1.46)                  | 0.58  |
| Day-to-day | 28 | 1.42 (1.07 - 1.88)    | 0.02  | 1.28 (0.91 - 1.81)                  | 0.16  |
| Awake | 26 | 1.32 (0.94 - 1.85)    | 0.11  | 1.24 (0.88 - 1.76)                  | 0.22  |

| CV Death or MACE |    |                       |       |                                     |       |
| Bt-to-bt | 37 | 1.21 (0.96 - 1.52)    | 0.10  | 1.16 (0.92 - 1.46)                  | 0.22  |
| Day-to-day | 38 | 1.21 (0.92 - 1.58)    | 0.17  | 1.18 (0.89 - 1.57)                  | 0.25  |
| Awake | 38 | 1.27 (0.96 - 1.68)    | 0.10  | 1.36 (1.01 - 1.84)                  | 0.04  |

| Death or MACE |    |                       |       |                                     |       |
| Bt-to-bt | 53 | 1.16 (0.94 - 1.43)    | 0.17  | 1.09 (0.88 - 1.34)                  | 0.44  |
| Day-to-day | 55 | 1.23 (0.99 - 1.54)    | 0.07  | 1.16 (0.91 - 1.48)                  | 0.22  |
| Awake | 54 | 1.26 (0.99 - 1.59)    | 0.06  | 1.31 (1.02 - 1.67)                  | 0.04  |
### Supplemental Table IV. Risk of cardiovascular events during follow up, according to mean SBP on each method of BP measurement.

Results are presented as hazard ratios (Cox Proportional Hazards) per SD increase in mean SBP for all patients undergoing each form of monitoring, with 95% confidence intervals, unadjusted and adjusted for age and gender. Bt-to-bt beat to beat BP variability; p-val=p value;

<table>
<thead>
<tr>
<th>Measure</th>
<th>Ev</th>
<th>Unadjusted HR (95%CI)</th>
<th>p-val</th>
<th>Adjusted for Age/Gender HR (95%CI)</th>
<th>p-val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ischaemic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>23</td>
<td>1.55 (1.15 - 2.09)</td>
<td>0.004</td>
<td>1.56 (1.15 - 2.12)</td>
<td>0.005</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>22</td>
<td>1.61 (1.20 - 2.16)</td>
<td>0.002</td>
<td>1.58 (1.17 - 2.13)</td>
<td>0.003</td>
</tr>
<tr>
<td>Awake</td>
<td>23</td>
<td>1.65 (1.19 - 2.30)</td>
<td>0.003</td>
<td>1.68 (1.21 - 2.35)</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Any Stroke</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>34</td>
<td>1.44 (1.08 - 1.92)</td>
<td>0.01</td>
<td>1.44 (1.07 - 1.93)</td>
<td>0.02</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>33</td>
<td>1.56 (1.19 - 2.06)</td>
<td>0.002</td>
<td>1.56 (1.17 - 2.07)</td>
<td>0.002</td>
</tr>
<tr>
<td>Awake</td>
<td>33</td>
<td>1.60 (1.17 - 2.17)</td>
<td>0.003</td>
<td>1.59 (1.16 - 2.19)</td>
<td>0.004</td>
</tr>
<tr>
<td><strong>All cause</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>24</td>
<td>1.47 (1.10 - 1.98)</td>
<td>0.01</td>
<td>1.43 (1.04 - 1.96)</td>
<td>0.03</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>28</td>
<td>1.40 (1.03 - 1.92)</td>
<td>0.03</td>
<td>1.64 (1.16 - 2.32)</td>
<td>0.005</td>
</tr>
<tr>
<td>Awake</td>
<td>26</td>
<td>1.52 (1.08 - 2.15)</td>
<td>0.02</td>
<td>1.42 (0.95 - 2.12)</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>CV Death or</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>37</td>
<td>1.61 (1.24 - 2.08)</td>
<td>&lt;0.001</td>
<td>1.59 (1.21 - 2.08)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>38</td>
<td>1.71 (1.33 - 2.19)</td>
<td>&lt;0.001</td>
<td>1.73 (1.33 - 2.23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Awake</td>
<td>38</td>
<td>1.67 (1.25 - 2.22)</td>
<td>&lt;0.001</td>
<td>1.60 (1.19 - 2.16)</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Death or</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MACE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>53</td>
<td>1.62 (1.31 - 2.00)</td>
<td>&lt;0.001</td>
<td>1.56 (1.24 - 1.95)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>55</td>
<td>1.59 (1.28 - 1.97)</td>
<td>&lt;0.001</td>
<td>1.66 (1.32 - 2.08)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Awake</td>
<td>54</td>
<td>1.69 (1.33 - 2.15)</td>
<td>&lt;0.001</td>
<td>1.58 (1.23 - 2.04)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Supplemental Table V. Relationship between BP variability on home or beat-to-beat monitoring and the risk of recurrent cardiovascular events, adjusted for both forms of monitoring. Results are presented as hazard ratios per standard deviation increase in BPV. Bt-to-bt= beat to beat BP variability; p-val=p value;

<table>
<thead>
<tr>
<th>Measure</th>
<th>Unadjusted</th>
<th>Adjusted for Age/Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95%CI)</td>
<td>p-val</td>
</tr>
<tr>
<td><strong>Ischaemic Stroke</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>1.41 (1.05 - 1.90)</td>
<td>0.02</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>1.18 (0.83 - 1.68)</td>
<td>0.37</td>
</tr>
<tr>
<td><strong>Any Stroke</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>1.38 (1.06 - 1.81)</td>
<td>0.02</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>1.25 (0.92 - 1.71)</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Death</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>1.22 (0.86 - 1.73)</td>
<td>0.27</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>1.40 (0.96 - 2.03)</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>CV death or MACE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>1.30 (1.01 - 1.67)</td>
<td>0.05</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>1.39 (1.06 - 1.82)</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Death or MACE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bt-to-bt</td>
<td>1.19 (0.96 - 1.49)</td>
<td>0.12</td>
</tr>
<tr>
<td>Day-to-day</td>
<td>1.43 (1.15 - 1.78)</td>
<td>0.002</td>
</tr>
</tbody>
</table>
Supplemental Figure I. Agreement between BPV recorded on two separate occasions with either beat-to-beat or home monitoring. Panels A + B show scatter plots comparing the first and second recording of BPV over 5 minutes of beat-to-beat recording (A) or 1 week of day-to-day home recording (B). Panels C+D show the equivalent Bland-Altman plots for agreement between the two measurements.
Supplemental Figure II. Effect of adjustment for regression to the mean on the relationship between BPV on beat-to-beat or home BP monitoring and the risk of recurrent cardiovascular events or death. Hazard ratios for the risk of recurrent events for each quartile of BPV on beat-to-beat or home monitoring relative to the lowest quartile are shown, before (A) and after (B) adjustment for regression to the mean. Difference between the mean BPV for each quartile and the population mean was adjusted by the intraclass correlation coefficient from repeatability studies.
Supplemental Table VI. Differences in mean SBPV on beat-to-beat and home day-to-day monitoring for patients experiencing recurrent events. Results are presented as mean (standard deviation) for patients affected or unaffected by each outcome event. P-values (p-val) are presented for t-tests. MACE = Major adverse cardiovascular events, CVS = cardiovascular, CV = coefficient of variation.

<table>
<thead>
<tr>
<th>Event</th>
<th>Beat-to-beat BPV</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unaffected</td>
<td>Affected</td>
<td>p-val</td>
<td>Unaffected</td>
<td>Affected</td>
</tr>
<tr>
<td><strong>Ischaemic Stroke</strong></td>
<td>4.68 (2.4)</td>
<td>6.24 (3.6)</td>
<td>0.001</td>
<td>4.75 (1.8)</td>
<td>5.19 (1.7)</td>
</tr>
<tr>
<td><strong>Any Stroke</strong></td>
<td>4.66 (2.4)</td>
<td>6.16 (3.6)</td>
<td>0.001</td>
<td>4.74 (1.8)</td>
<td>5.34 (1.6)</td>
</tr>
<tr>
<td><strong>All cause mortality</strong></td>
<td>4.70 (2.5)</td>
<td>6.14 (3.3)</td>
<td>0.006</td>
<td>4.73 (1.8)</td>
<td>5.45 (1.5)</td>
</tr>
<tr>
<td><strong>CV Death or MACE</strong></td>
<td>4.66 (2.4)</td>
<td>5.97 (3.5)</td>
<td>0.002</td>
<td>4.71 (1.7)</td>
<td>5.46 (1.9)</td>
</tr>
<tr>
<td><strong>Death or MACE</strong></td>
<td>4.60 (2.4)</td>
<td>5.98 (3.5)</td>
<td>0.03</td>
<td>4.68 (1.8)</td>
<td>5.44 (1.7)</td>
</tr>
</tbody>
</table>